COMBINATION THERAPY FOR TREATING CANCER
The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR 1)modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | LEUKOS BIOTECH, S.L |
| description | The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR 1)modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy. |
| format | Patent |
| fullrecord | <record><control><sourceid>uspatents_EFI</sourceid><recordid>TN_cdi_uspatents_applications_17818841</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20230122940</sourcerecordid><originalsourceid>FETCH-uspatents_applications_178188413</originalsourceid><addsrcrecordid>eNrjZFB39vd18vRzDPH091MI8XANcgyIVHDzD1IICXIFCvq5Kzg7-jm7BvEwsKYl5hSn8kJpbgY1N9cQZw_d0uKCxJLUvJLi-MSCgpzM5MSSzPy84nhDcwtDCwsTQ2OiFQIA1yApxQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>COMBINATION THERAPY FOR TREATING CANCER</title><source>USPTO Published Applications</source><creator>LEUKOS BIOTECH, S.L</creator><creatorcontrib>LEUKOS BIOTECH, S.L</creatorcontrib><description>The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR 1)modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.</description><language>eng</language><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20230122940$$EPDF$$P50$$Guspatents$$Hfree_for_read</linktopdf><link.rule.ids>230,308,777,870,882,64038</link.rule.ids><linktorsrc>$$Uhttps://patentcenter.uspto.gov/applications/17818841$$EView_record_in_USPTO$$FView_record_in_$$GUSPTO$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>LEUKOS BIOTECH, S.L</creatorcontrib><title>COMBINATION THERAPY FOR TREATING CANCER</title><description>The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR 1)modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EFI</sourceid><recordid>eNrjZFB39vd18vRzDPH091MI8XANcgyIVHDzD1IICXIFCvq5Kzg7-jm7BvEwsKYl5hSn8kJpbgY1N9cQZw_d0uKCxJLUvJLi-MSCgpzM5MSSzPy84nhDcwtDCwsTQ2OiFQIA1yApxQ</recordid><startdate>20220810</startdate><enddate>20220810</enddate><creator>LEUKOS BIOTECH, S.L</creator><scope>EFI</scope></search><sort><creationdate>20220810</creationdate><title>COMBINATION THERAPY FOR TREATING CANCER</title></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-uspatents_applications_178188413</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>online_resources</toplevel><creatorcontrib>LEUKOS BIOTECH, S.L</creatorcontrib><collection>USPTO Published Applications</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><aucorp>LEUKOS BIOTECH, S.L</aucorp><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>COMBINATION THERAPY FOR TREATING CANCER</title><date>2022-08-10</date><risdate>2022</risdate><abstract>The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR 1)modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_uspatents_applications_17818841 |
| source | USPTO Published Applications |
| title | COMBINATION THERAPY FOR TREATING CANCER |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T14%3A19%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-uspatents_EFI&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.aucorp=LEUKOS%20BIOTECH,%20S.L&rft.date=2022-08-10&rft_id=info:doi/&rft_dat=%3Cuspatents_EFI%3E20230122940%3C/uspatents_EFI%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |